Hikma Pharmaceuticals (LON:HIK) had its price target increased by Jefferies Group from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) in a research report released on Monday. They currently have a hold rating on the stock.
Several other analysts have also recently weighed in on HIK. Morgan Stanley reissued an equal weight rating and issued a GBX 1,100 ($14.80) price objective on shares of Hikma Pharmaceuticals in a research note on Friday, December 1st. J P Morgan Chase & Co restated a neutral rating on shares of Hikma Pharmaceuticals in a report on Friday, September 29th. Numis Securities restated an add rating and issued a GBX 1,560 ($21.00) target price on shares of Hikma Pharmaceuticals in a report on Friday, August 11th. Citigroup restated a neutral rating and issued a GBX 1,350 ($18.17) target price on shares of Hikma Pharmaceuticals in a report on Thursday, August 24th. Finally, Peel Hunt restated a hold rating and issued a GBX 1,390 ($18.71) target price on shares of Hikma Pharmaceuticals in a report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of Hold and an average price target of GBX 1,188.90 ($16.00).
Shares of Hikma Pharmaceuticals (LON HIK) opened at GBX 964.13 ($12.98) on Monday. Hikma Pharmaceuticals has a one year low of GBX 906.50 ($12.20) and a one year high of GBX 2,346 ($31.57).
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/08/jefferies-group-raises-hikma-pharmaceuticals-hik-price-target-to-gbx-1074.html.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.